Alliance for Clinical Trials in Oncology

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Alliance for Clinical Trials in Oncology sits in the top decile of US sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count).

446 total trials 29 currently recruiting 346 completed early-phase tilt top decile by trial count

Alliance for Clinical Trials in Oncology: 446 sponsored US clinical trials, 29 recruiting.

Alliance for Clinical Trials in Oncology sponsors 446 registered US clinical trials on ClinicalTrials.gov, 29 of them currently recruiting, and 346 completed. 142 of these trials are in Phase 3-4 (later-stage) and 235 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 19 trials.

Top-decile sponsor footprint

Alliance for Clinical Trials in Oncology ranks in the top decile of sponsors by registered trial count (#80 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

346 of 377 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

446 total, page 5 of 9

COMPLETED

Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

NCT00376597

COMPLETED Phase 2

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer

NCT00114231

COMPLETED Phase 2

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00268489

COMPLETED

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

NCT00316836

TERMINATED Phase 2

Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

NCT00268437

COMPLETED Phase 2

Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab

NCT00238238

COMPLETED Phase 2

Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00227565

COMPLETED Phase 2

Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery

NCT00316862

COMPLETED Phase 3

Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery

NCT00316914

COMPLETED Phase 2

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

NCT00301821

COMPLETED Phase 2

Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer

NCT00311610

COMPLETED Phase 2

Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00124618

COMPLETED Phase 3

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00265759

COMPLETED Phase 3

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00265850

COMPLETED Phase 3

Octreotide in Treating Patients With Cancer-Related Malignant Ascites

NCT00182754

COMPLETED

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

NCT00115505

COMPLETED Phase 2

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00117962

COMPLETED Phase 2

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00107510

COMPLETED Phase 2

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

NCT00100945

COMPLETED Phase 3

Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

NCT00107172

COMPLETED Phase 2

Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

NCT00112528

COMPLETED Phase 2

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

NCT00117975

COMPLETED Phase 3

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00118209

COMPLETED Phase 2

Everolimus in Treating Patients With Stage IV Melanoma

NCT00098553

COMPLETED Phase 2

Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00056030

COMPLETED NA

Tetracycline in Preventing Skin Rash in Patients Who Are Receiving Drugs Such as Gefitinib and Cetuximab for Cancer

NCT00091247

COMPLETED Phase 3

Creatine in Treating Patients With Cancer-Associated Weight Loss

NCT00081250

COMPLETED Phase 3

Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

NCT00087399

COMPLETED Phase 2

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

NCT00098774

COMPLETED Phase 2

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

NCT00062062

COMPLETED NA

Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer

NCT00089310

COMPLETED Phase 3

Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis

NCT00091351

COMPLETED Phase 2

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

NCT00093808

COMPLETED Phase 2

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00077311

COMPLETED

Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer

NCT00899782

COMPLETED Phase 2

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma

NCT00086801

COMPLETED Phase 3

Lidocaine Patch in Treating Cancer Patients With Neuropathic Pain After Surgery

NCT00058357

COMPLETED Phase 2

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00062114

COMPLETED Phase 3

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

NCT00075855

COMPLETED Phase 2

Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer

NCT00079118

TERMINATED Phase 3

Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors

NCT00072215

COMPLETED Phase 3

Combination Chemotherapy in Treating Patients With Bladder Cancer

NCT00014534

COMPLETED Phase 2

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

NCT00066781

COMPLETED Phase 3

Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00068445

COMPLETED

Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who Are Undergoing Lung Resection for Suspicious Stage I Lung Lesions

NCT00077324

COMPLETED

Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2

NCT00896701

COMPLETED Phase 1

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

NCT00059865

COMPLETED Phase 2

Lycopene in Treating Patients With Metastatic Prostate Cancer

NCT00068731

COMPLETED Phase 2

Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission

NCT00070135

COMPLETED Phase 3

Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases

NCT00079001

← Previous Page 5 of 9 Next →

What is open in the Alliance for Clinical Trials in Oncology pipeline

29 recruiting of 446 indexed (7% open); 346 completed (78%).

Phase mix: 142 late (III/IV) vs 235 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (19 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Alliance for Clinical Trials in Oncology: open-pipeline peers nationwide

Peers matched on 446 registered trials and 7% open enrollment, not the therapeutic-area sidebar.

Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 5%10%15%20%25% Total trials Recruiting share Alliance for Clinical Trials in OncologyMedical College of WisconsinUniversity of VirginiaChildren's Hospital of PhiladelphiaNovo Nordisk A/SNational Institutes of Health Clinical Center (CC)Insmed IncorporatedNICHD Neonatal Research NetworkHennepin Healthcare Research Institute
Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Alliance for Clinical Trials in Oncology sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 446 trials (± recruiting share)

Sponsors near 7% open enrollment (± trial volume)

What to do with this Alliance for Clinical Trials in Oncology page

446 registered trials is a research-attention snapshot, not an endorsement of Alliance for Clinical Trials in Oncology or any single study.

  • 29 of Alliance for Clinical Trials in Oncology's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Alliance for Clinical Trials in Oncology studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Alliance for Clinical Trials in Oncology pipeline card: 446 registered trials from official public datasets.Report a data error.